# Amphastar Pharmaceuticals, Inc. (AMPH) FY2026 YTD Q2 P&L / Income Statement

- Company: Amphastar Pharmaceuticals, Inc. (AMPH)
- Period: 2026-01-01 to 2026-06-30
- Filing: Q2 FY2026 10-Q, filed 2026-08-06, accession number 0001297184-26-000047
- Page: https://plicit.ai/financials/amph/fy2026-ytd-q2-income-statement
- Chart image: https://plicit.ai/charts/amph-fy2026-ytd-q2-income-statement-sankey.png

## Chart details: Revenue by Business Segment by Subsegment

Income statement for 2026-01-01 through 2026-06-30. View: Segments by Subsegments. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Revenues**: 355,074,000 US dollars
- **Cost of revenues**: 191,282,000 US dollars
- **Gross profit**: 163,792,000 US dollars
- **Total operating expenses**: 110,433,000 US dollars
- **Income from operations**: 53,359,000 US dollars
- **Total non-operating income (expenses), net**: negative 4,763,000 US dollars
- **Income before income taxes**: 48,596,000 US dollars
- **Income tax provision**: 11,828,000 US dollars
- **Net income**: 36,768,000 US dollars
- **Finished Pharmaceutical Products Segment - BAQSIMI**: 77,937,000 US dollars
- **Finished Pharmaceutical Products Segment - Epinephrine**: 35,067,000 US dollars
- **Finished Pharmaceutical Products Segment - Glucagon**: 21,075,000 US dollars
- **Finished Pharmaceutical Products Segment - Ipratropium Bromide**: 8,411,000 US dollars
- **Finished Pharmaceutical Products Segment - Lidocaine**: 28,499,000 US dollars
- **Finished Pharmaceutical Products Segment - Other Products**: 133,318,000 US dollars
- **Finished Pharmaceutical Products Segment - Primatene MIST**: 50,767,000 US dollars
- **Research and development**: 48,901,000 US dollars
- **General and administrative**: 36,270,000 US dollars
- **Selling, distribution, and marketing**: 25,262,000 US dollars

### Chart connections

- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.

## Chart details: Revenue by Geography

- Page: https://plicit.ai/financials/amph/fy2026-ytd-q2-income-statement/revenue-by-geography
- Chart image: https://plicit.ai/charts/amph-fy2026-ytd-q2-revenue-by-geography-sankey.png

Income statement for 2026-01-01 through 2026-06-30. View: Geography. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Revenues**: 355,074,000 US dollars
- **Cost of revenues**: 191,282,000 US dollars
- **Gross profit**: 163,792,000 US dollars
- **Total operating expenses**: 110,433,000 US dollars
- **Income from operations**: 53,359,000 US dollars
- **Total non-operating income (expenses), net**: negative 4,763,000 US dollars
- **Income before income taxes**: 48,596,000 US dollars
- **Income tax provision**: 11,828,000 US dollars
- **Net income**: 36,768,000 US dollars
- **United States**: 331,382,000 US dollars
- **China**: 7,042,000 US dollars
- **France**: 16,650,000 US dollars
- **Research and development**: 48,901,000 US dollars
- **General and administrative**: 36,270,000 US dollars
- **Selling, distribution, and marketing**: 25,262,000 US dollars

### Chart connections

- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.